Artificial Intelligence | News | Insights | AiThority
[bsfp-cryptocurrency style=”widget-18″ align=”marquee” columns=”6″ coins=”selected” coins-count=”6″ coins-selected=”BTC,ETH,XRP,LTC,EOS,ADA,XLM,NEO,LTC,EOS,XEM,DASH,USDT,BNB,QTUM,XVG,ONT,ZEC,STEEM” currency=”USD” title=”Cryptocurrency Widget” show_title=”0″ icon=”” scheme=”light” bs-show-desktop=”1″ bs-show-tablet=”1″ bs-show-phone=”1″ custom-css-class=”” custom-id=”” css=”.vc_custom_1523079266073{margin-bottom: 0px !important;padding-top: 0px !important;padding-bottom: 0px !important;}”]

John Baldoni, ex-GSK R&D Leader, Joins BioSymetrics as Strategic Advisor

BioSymetrics, a phenomics-driven AI drug discovery company, announced that John Baldoni will join its strategic advisory board. John is a pharmaceutical industry veteran with more than 40 years of experience, including 29 years at GSK. As an advisor to BioSymetrics, he will support the advancement of the company’s target discovery platform and drug discovery programs, as well as advise on pharmaceutical partnering deals.

An early champion of AI applications to accelerate drug discovery, John seeks out promising startups for advisory roles, which led him to BioSymetrics. Said John: “I am always looking for companies that can generate large amounts of relevant and consistent data to increase the chances of getting a drug to market and improve outcomes for patients faster. What is compelling about BioSymetrics is the coupling of their clinical and genomics insight directly with their biological assays. Their process is poised to improve translation of potential targets and reduce downstream failure in clinical trials.”

AI and ML NewsAn Investment Into Artificial Intelligence as Daktela Buys

Added John: “Ultimately, we need to change how targets are evaluated and pursued – in silico first – and BioSymetrics is taking that approach with its phenomics-driven target discovery platform.”

Related Posts
1 of 33,580

John has participated in the research and development of many commercial medicines. He was previously SVP, Platform Technology and Science at GSK, SVP of in-silico drug discovery at GSK, and CTO of Valo Health. John conceptualized, founded, and is currently CEO of the ATOM consortium, a public-private partnership advancing drug discovery through a pre-competitive platform that integrates diverse data and high-performance computing.

“John is a rare person who can combine decades of pharmaceutical industry experience with a passion for continued innovation and improvement, using technology. We are thrilled he is joining BioSymetrics as an advisor,” said Anthony Iacovone, Co-Founder and CEO, BioSymetrics. “His counsel is highly valued as we continue to advance the development of our Elion platform and our first discovery programs across diseases of critical unmet need.”

WEB3 Gaming and NFT News : P2E.Game: The One-Stop Portal for WEB3 Gaming and NFT

[To share your insights with us, please write to]

Comments are closed.